Presbyopia: A Broadening Market Accommodates New Medtech Innovations
This article was originally published in Start Up
The arrival of a new generation of intraocular lenses and corneal inlays – designed to offer clearer, improved vision without the need for reading glasses – is expected to spur growth in the presbyopia market.
You may also be interested in...
In the ophthalmic device sector, intraocular lens surgery is expanding way beyond the cataract market with paradigm shifting technology. The vast presbyopia market now has an FDA-approved "corneal inlay" option, micro invasive glaucoma surgery has created an entirely new device segment, and corneal cross-linking has the potential to transcend its role as an effective treatment for a corneal disease to possibly being the next big thing in the non-surgical treatment of refractive errors.
After years of discussions, Japan has revised legislation relating to the use of medicines containing cannabinoids, while also officially criminalizing the non-medical use of marijuana. The move may pave the way for easier use of medicines such as Epidiolex, for which a local Phase III trial started in 2022.
Major Chinese biopharma contract services group WuXi Biologics' share price plummeted after it said external factors would contribute to it missing original revenue targets this year in multiple areas.